Pharma Major Lupin announced today that it has received final approval for its Lamivudine tablets 150 mg and 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ViiV Healthcare's Epivir® tablets 150 mg and 300 mg. Lupin Pharmaceuticals Inc. (LPI), the company’s US subsidiary would commence marketing the product shortly.
Lupin's Lamivudine tablets 150 mg and 300 mg are the AB-rated generic equivalents of ViiV Healthcare's Epivir tablets and are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. Limitation of use: The dosage of this product is for HIV-1 and not for HBV.
Epivir® Tablets had annual U.S sales of USD 39.7 million (IMS MAT September, 2014).
Shares of the company gained Rs 3.65, or 0.26%, to settle at Rs 1,406.40. The total volume of shares traded was 21,180 at the BSE (Friday).